{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T20:18:46Z","timestamp":1776889126312,"version":"3.51.2"},"reference-count":47,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,2,5]],"date-time":"2016-02-05T00:00:00Z","timestamp":1454630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Pathology CR"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Histone deacetylases (HDAC) are key players in epigenetic regulation of gene expression and HDAC inhibitor (HDACi) treatment seems to be a promising anticancer therapy in many human tumours, including soft tissue sarcomas. HR23b has been shown to be a potential biomarker for sensitivity to HDACi therapy in cutaneous T\u2010cell lymphoma and hepatocellular carcinoma. We aimed to evaluate HR23b as a candidate biomarker for HDACi response in sarcomas and gastrointestinal stromal tumours (GIST). Therefore, HR23b expression was analysed comprehensively by western blot in sarcoma and GIST cell lines covering all major clinically relevant subtypes. MTT assay and ApoTox\u2010Glo<jats:sup>TM<\/jats:sup> Triplex assay were performed after treatment with vorinostat, belinostat, mocetinostat and entinostat. HR23b protein expression was measured under HDACi treatment. Furthermore, HR23b expression levels were immunohistochemically determined in a large set of 523 clinical samples from sarcoma and GIST patients. Western blot analyses showed that sarcomas differ significantly in their expression of HR23b protein. All HDACi were able to regulate proliferation and apoptosis <jats:italic>in vitro<\/jats:italic>. Sensitivity to vorinostat correlated significantly with HR23b protein expression. Immunohistochemical prevalence screening in clinical samples of relevant adult\u2010type tumours revealed that 12.5% of sarcomas (among them malignant peripheral nerve sheath tumours, pleomorphic liposarcomas, leiomyosarcomas, dedifferentiated liposarcomas, synovial sarcomas and angiosarcomas) and 23.2% of GIST show high HR23b expression. Therefore, HDACi have antiproliferative and proapoptotic effects in sarcomas depending on the expression level of HR23b. These findings suggest that HR23b represents a candidate biomarker for HDACi sensitivity in certain sarcoma types and in GIST.<\/jats:p>","DOI":"10.1002\/cjp2.35","type":"journal-article","created":{"date-parts":[[2015,12,23]],"date-time":"2015-12-23T11:20:53Z","timestamp":1450869653000},"page":"59-71","source":"Crossref","is-referenced-by-count":12,"title":["HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat"],"prefix":"10.1002","volume":"2","author":[{"given":"Michaela","family":"Angelika Ihle","sequence":"first","affiliation":[{"name":"Institute of Pathology, University Hospital Cologne Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Merkelbach\u2010Bruse","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital Cologne Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital Cologne Cologne Germany"},{"name":"Gerhard Domagk Institute of Pathology, University Hospital M\u00fcnster M\u00fcnster Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Bauer","sequence":"additional","affiliation":[{"name":"Sarcoma Center, West German Cancer Center, University of Essen Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Ratner","sequence":"additional","affiliation":[{"name":"US Department of Pediatrics Cincinnati Children's Hospital Medical Centre Cincinnati OH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Sonobe","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Chugoku Central Hospital Fukuyama Hiroshima Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Nishio","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Orthopaedic Surgery Fukuoka University Fukuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olle","family":"Larsson","sequence":"additional","affiliation":[{"name":"Department of Oncology and Pathology The Karolinska Institute Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"\u00c5man","sequence":"additional","affiliation":[{"name":"Sahlgrenska Cancer Centre, University of Gothenburg Gothenburg Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Pedeutour","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Laboratory of Genetics of Solid Tumours Institute for Research on Cancer and Aging Nice France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Taguchi","sequence":"additional","affiliation":[{"name":"Division of Human Health &amp; Medical Science, Graduate School of Kuroshio Science Kochi University Nankoku Kochi Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Wardelmann","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital Cologne Cologne Germany"},{"name":"Gerhard Domagk Institute of Pathology, University Hospital M\u00fcnster M\u00fcnster Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Buettner","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital Cologne Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans\u2010Ulrich","family":"Schildhaus","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital Cologne Cologne Germany"},{"name":"Institute of Pathology, University Hospital G\u00f6ttingen G\u00f6ttingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,2,5]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2133"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-006-9142-0"},{"issue":"10","key":"e_1_2_7_4_1","first-page":"3578","article-title":"Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously","volume":"9","author":"Kelly WK","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.02.047"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2008.01102.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2146\/news140056"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2011.577737"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70265-0"},{"key":"e_1_2_7_10_1","unstructured":"US National Institutes of Health Clinical Trials. U.S. National Institutes of Health; Available from:www.clinicaltrials.govSeptember 2015."},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-11-0214"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.313"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2008.08.016"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.12.001"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.17.12.6924"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.32607\/20758251-2014-6-1-23-34"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M404020200"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2005.04667.x"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2014.10.004"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.2395"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0913912107"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.442"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv033"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq381"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/148614"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.3233\/CBM-2008-4206"},{"key":"e_1_2_7_27_1","first-page":"8492","article-title":"The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells","volume":"61","author":"Munster PN","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005721114555"},{"key":"e_1_2_7_29_1","first-page":"1585","article-title":"Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy\u2010associated cell death in chondrosarcoma cell lines","volume":"28","author":"Yamamoto S","year":"2008","journal-title":"Anticancer Res"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-4004"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0560"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.01.010"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-49"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2014.04.021"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.7.4.583"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.013870"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.2434"},{"key":"e_1_2_7_38_1","first-page":"462","article-title":"Histone deacetylase inhibitors in the treatment of lymphoma","volume":"10","author":"Lemoine M","year":"2010","journal-title":"Discov Med"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.25941"},{"key":"e_1_2_7_40_1","first-page":"4125","article-title":"Identification and evaluation of potential anti\u2010cancer drugs on human neuroendocrine tumor cell lines","volume":"26","author":"Larsson DE","year":"2006","journal-title":"Anticancer Res"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20070779"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2013.47"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-69"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.9411"},{"key":"e_1_2_7_45_1","first-page":"1349","article-title":"Abnormal expression of cell cycle regulators in FUS\u2010CHOP carrying liposarcomas","volume":"25","author":"Olofsson A","year":"2004","journal-title":"Int J Oncol"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/208786"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2264(199901)24:1<30::AID-GCC5>3.0.CO;2-P"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2006.09.001"}],"container-title":["The Journal of Pathology: Clinical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcjp2.35","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cjp2.35","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cjp2.35","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pathsocjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cjp2.35","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:19:20Z","timestamp":1760275160000},"score":1,"resource":{"primary":{"URL":"https:\/\/pathsocjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cjp2.35"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,5]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1002\/cjp2.35"],"URL":"https:\/\/doi.org\/10.1002\/cjp2.35","archive":["Portico"],"relation":{},"ISSN":["2056-4538","2056-4538"],"issn-type":[{"value":"2056-4538","type":"print"},{"value":"2056-4538","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,5]]}}}